A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE

• Status: Recruiting
• Trial end date: 2026-07-23
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to measure the efficacy and safety of durvalumab intravenous (IV) solution plus bevacizumab IV solution after transarterial radioembolization (Yttrium 90 glass microspheres TARE) in participants with unresectable hepatocellular carcinoma (HCC) amenable to embolization.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Bevacizumab; Durvalumab

Criteria

Inclusion Criteria:

• Participants with confirmed unresectable HCC

• Participants with Lung dose threshold for Yttrium 90 glass microspheres of 30 Gy (equal or less than 30 Gy per treatment for glass) and an estimated Future liver remnant volume (FLRV) ≥ 30% of whole liver volume

• Participants with no evidence of extrahepatic disease on any available imaging

• Participants with one or more measurable lesions, unilobar disease for participants with segmental or right anterior/posterior portal vein invasion (Vp1/Vp2) and eligible for Yttrium 90 glass microspheres TARE.

• Participants having Child-Pugh score class A.

• Participants having ECOG performance status of 0 or 1 at enrollment

• Adequate organ and marrow function

Exclusion Criteria:

• Disease amenable to curative surgery or transplantation or curative ablation.

• Participants co-infected with HBV and HDV

• Any history of nephrotic or nephritic syndrome.

• Clinically significant (eg, active) cardiovascular disease

• Participants with uncontrolled hypertension

• History of hepatic encephalopathy

• Known hereditary predisposition to bleeding or thrombosis; any prior or current evidence of bleeding diathesis.

• Receipt of more than 1 prior embolization (TACE or TARE) treatment/procedure

• Participant has received any prior anticancer systemic therapy for unresectable HCC.

• History of arterial thrombotic event, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack, within 6 months prior to enrollment.

• History of abdominal fistula or gastrointestinal (GI) perforation, non-healed gastric ulcer that is refractory to treatment, or active GI bleeding within 6 months prior to enrollment